Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 751 of 5804
-
Experimental drug auxora shows promise in severe COVID-19 pneumonia trial
Disease control CompletedPart 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia. Part 2 of this study randomized 284 patients and was a randomized, double blind, placebo-controlled (RCT) s…
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Family program aims to shield kids of melanoma survivors from the sun
Prevention CompletedThe overall purpose of this study is to determine the efficacy of the Family Lifestyles, Actions, and Risk Education (FLARE) intervention in improving melanoma preventive behaviors. Parent-child dyads, consisting of survivors of melanoma and their children, will be randomly assig…
Phase: NA • Sponsor: University of Utah • Aim: Prevention
Last updated Jul 12, 2026 00:00 UTC
-
New Three-Drug combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advance…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for Hard-to-Treat myeloma: targeted drug faces final test
Disease control OngoingThis open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belanta…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Breakthrough test could save kids from deadly TB meningitis
Diagnosis CompletedThe rapid diagnosis of tuberculosis (TB) in children remains a serious challenge owing to limitations in the existing diagnostic tests. TB meningitis (TBM), an extrapulmonary form of TB, is the most severe manifestation of paediatric TB. TBM results in high morbidity and mortalit…
Sponsor: University of Stellenbosch • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New combo targets sarcoma in limbs
Disease control Recruiting nowThe purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment tha…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New stent aims to save legs from amputation in severe artery disease
Disease control OngoingRandomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to…
Phase: NA • Sponsor: Micro Medical Solution, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New heart pump aims to keep patients alive without major complications
Disease control TerminatedThis is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3 LVAS).
Phase: NA • Sponsor: Evaheart, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to stop High-Risk prostate cancer from spreading
Disease control OngoingThe purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recu…
Phase: PHASE3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for ALK+ lung cancer: brigatinib trial underway
Disease control CompletedThis is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to outsmart tough leukemia without chemo
Disease control OngoingThe purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the response to standard-of-care treatment of corticosteroids + TKI therapy by adding the s…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can an arthritis drug tame severe COVID-19? trial results in.
Disease control CompletedPrimary Objective: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19). Secondary Objectives: * Evaluate the 28-day survival rate. * Evaluate the clinical effi…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo aims to prevent leukemia return after remission
Disease control CompletedThis study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZ…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Blood test triggers early immunotherapy in bladder cancer trial
Disease control OngoingImmunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown strong predictive value for patient selection. Moreover, the term 'metastatic' is base…
Phase: PHASE2 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, wor…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Major trial tests new antibody drug for hospitalized COVID-19 patients
Disease control CompletedDisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents in ho…
Phase: PHASE3 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could poop transplants spare kids with Crohn's from strong drugs?
Disease control Recruiting nowTo explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a drug keep hidradenitis suppurativa under control for years?
Disease control OngoingThe purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and toler…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for hard-to-treat endometrial cancer: targeted drug shows promise in early trial
Disease control OngoingThis is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC